Metronomic doses of temozolomide enhance the efficacy of carbon nanotube CPG immunotherapy in an invasive glioma model

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Ouyang, Mao ^a   White, Ethan E ^b   Ren, Hui ^c   Guo, Qin ^a   Zhang, Ian ^b   Gao, Hang ^d   Yanyan, Song ^c   Chen, Xuebo ^e   Weng, Yiming ^b   Da Fonseca, Anna ^f   Shah, Sunny ^b   Manuel, Edwin R ^b   Zhang, Leying ^b   Vonderfecht, Steven L ^b   Alizadeh, Darya ^b   Berlin, Jacob M ^b   Badie, Behnam ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^e CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; LIPID; MACROGOL; SINGLE WALLED NANOTUBE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CPG-OLIGONUCLEOTIDE; DACARBAZINE; MACROGOL DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INTRACRANIAL DRUG ADMINISTRATION; METRONOMIC DRUG ADMINISTRATION; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; CELL DEATH; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOTHERAPY; PATHOLOGY; SPLEEN; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DACARBAZINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; IMMUNOTHERAPY; INFLAMMATION; LIPIDS; MICE, INBRED C57BL; NANOTUBES, CARBON; NEOPLASM INVASIVENESS; OLIGODEOXYRIBONUCLEOTIDES; POLYETHYLENE GLYCOLS; SPLEEN; TREATMENT OUTCOME;

EID: 84958825024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148139     Document Type: Article

References (39)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10 (5):459-66. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895.
2. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene therapy & molecular biology. 2006; 10(A):133.
3. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006; 10(A):133-46. Epub 2006/07/01. PMID: 16810329; PubMed Central PMCID: PMC1474813.
4. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 2008; 3(1):27-32. Epub 2009/03/04. doi: 10.1016/j.uct.2007.11.003 PMID: 19255607; PubMed Central PMCID: PMC2390897.
5. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-oncology. 2010; 12 (4):401-8. Epub 2010/03/24. doi: 10.1093/neuonc/nop047 PMID: 20308317; PubMed Central PMCID: PMC2940609.
6. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology. 2006; 8(1):60-6. doi: 10. 1215/S1522851705000475 PMID: 16443949; PubMed Central PMCID: PMC1871923.
7. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009; 115(17):3944-54. Epub 2009/06/19. doi: 10.1002/cncr. 24473 PMID: 19536884.
8. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008; 5(4):487-95. doi: 10.1021/mp800032f PMID: 18510338; PubMed Central PMCID: PMC2613572.
9. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nature immunology. 2004; 5(2):190-8. PMID: 14716310
10. Badie B, Berlin JM. The future of CpG immunotherapy in cancer. Immunotherapy. 2013; 5(1):1-3. doi: 10.2217/imt.12.148 PMID: 23256791
11. Zhao D, Alizadeh D, Zhang L, Liu W, Farrukh O, Manuel E, et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res. 2011; 17(4):771-82. Epub 2010/11/23. doi: 10.1158/1078-0432.CCR-10-2444 PMID: 21088258; PubMed Central PMCID: PMC3041854.
12. Fan H, Zhang I, Chen X, Zhang L, Wang H, Da Fonseca A, et al. Intracerebral CpG Immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clinical Cancer Research. 2012; 18(20):5628-38. doi: 10.1158/1078-0432.CCR-12-1911 PMID: 22904105
13. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PloS one. 2013; 8(3):e59082. doi: 10.1371/journal.pone.0059082 PMID: 23527092; PubMed Central PMCID: PMC3601076.
14. Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med. 2013; 11:135. doi: 10.1186/1479-5876-11-135 PMID: 23725550; PubMed Central PMCID: PMC3698134.
15. Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012; 2012:831090. doi: 10.1155/2012/831090 PMID: 23133490; PubMed Central PMCID: PMC3486128.
16. Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-oncology. 2011; 13(4):393-400. doi: 10.1093/neuonc/noq204 PMID: 21339188; PubMed Central PMCID: PMC3064696.
17. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010; 116(12):2868-77. doi: 10.1002/cncr.25035 PMID: 20564393.
18. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer immunology, immunotherapy: CII. 2009; 58(10):1627-34. Epub 2009/02/18. doi: 10.1007/s00262-009-0671-1 PMID: 19221744.
19. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006; 13(8):705-14. Epub 2006/01/20. doi: 3302717 [pii] doi: 10.1038/sj.gt.3302717 PMID: 16421599.
20. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(13):3399-408. Epub 2010/06/24. 1078-0432.CCR-09-3087 [pii] doi: 10.1158/1078-0432.CCR-09-3087 PMID: 20570924; PubMed Central PMCID: PMC3022005.
21. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjugate chemistry. 1993; 4(4):296-9. PMID: 8218486
22. Kim H-K, Wei H, Kulkarni A, Pogranichniy RM, Thompson DH. Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT. Biomacromolecules. 2012; 13(3):636-44. doi: 10.1021/bm2014119 PMID: 22229467
23. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 2009; 57(13):1458-67. Epub 2009/03/24. doi: 10.1002/glia.20863 PMID: 19306372.
24. Badie B, Schartner JM. Flow cytometric characterization of tumor-Associated macrophages in experimental gliomas. Neurosurgery. 2000; 46(4):957-61; discussion 61-2. Epub 2000/04/14. PMID: 10764271.
25. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer research. 2011; 71(12):4183-91. Epub 2011/04/30. doi: 0008-5472.CAN-10-4676 [pii] doi: 10.1158/0008-5472.CAN-10-4676 PMID: 21527558; PubMed Central PMCID: PMC3117077.
26. Lee TH, Cho HK, Cho YH, Lee MG. Development of an effective method for dendritic cell immunotherapy of mouse melanoma. Scand J Immunol. 2009; 70(2):85-92. Epub 2009/07/28. doi: SJI2273 [pii] doi: 10.1111/j.1365-3083.2009.02273.x PMID: 19630913.
27. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507(7493):519-22. doi: 10.1038/nature12978 PMID: 24531764
28. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nature reviews Drug discovery. 2012; 11(3):215-33. doi: 10.1038/nrd3626 PMID: 22301798.
29. Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer research. 2014; 74(10):2663-8. doi: 10.1158/0008-5472.CAN-14-0301 PMID: 24778417; PubMed Central PMCID: PMC4041515.
30. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WA, Seaton A, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nature nanotechnology. 2008; 3(7):423-8. doi: 10.1038/nnano.2008.111 PMID: 18654567.
31. Yamashita K, Yoshioka Y, Higashisaka K, Morishita Y, Yoshida T, Fujimura M, et al. Carbon nanotubes elicit DNA damage and inflammatory response relative to their size and shape. Inflammation. 2010; 33 (4):276-80. doi: 10.1007/s10753-010-9182-7 PMID: 20174859.
32. Drezek RA, Tour JM. Is nanotechnology too broad to practise? Nature nanotechnology. 2010; 5 (3):168-9. doi: 10.1038/nnano.2010.37 PMID: 20203616
33. Hurt RH, Monthioux M, Kane A. Toxicology of carbon nanomaterials: status, trends, and perspectives on the special issue. Carbon. 2006; 44(6):1028-33.
34. Schipper ML, Nakayama-Ratchford N, Davis CR, Kam NWS, Chu P, Liu Z, et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nature nanotechnology. 2008; 3 (4):216-21. doi: 10.1038/nnano.2008.68 PMID: 18654506
35. Liu Z, Davis C, Cai W, He L, Chen X, Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proceedings of the National Academy of Sciences. 2008; 105(5):1410-5.
36. Pulskamp K, Diabaté S, Krug HF. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicology letters. 2007; 168(1):58-74. PMID: 17141434
37. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Current opinion in chemical biology. 2005; 9(6):674-9. PMID: 16233988
38. Kolosnjaj-Tabi J, Hartman KB, Boudjemaa S, Ananta JS, Morgant G, Szwarc H, et al. In vivo behavior of large doses of ultrashort and full-length single-walled carbon nanotubes after oral and intraperitoneal administration to Swiss mice. Acs Nano. 2010; 4(3):1481-92. doi: 10.1021/nn901573w PMID: 20175510
39. Morimoto Y, Hirohashi M, Kobayashi N, Ogami A, Horie M, Oyabu T, et al. Pulmonary toxicity of welldispersed single-wall carbon nanotubes after inhalation. Nanotoxicology. 2012; 6(7):766-75. doi: 10. 3109/17435390.2011.620719 PMID: 21942532